Compare Novavax Inc (NVAX) vs D Wave Quantum Inc (QBTS) Price & Performance

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.

D-Wave Quantum (QBTS) trades at $14.60, down 4.07% with a bearish technical signal despite unanimous analyst buy ratings and a $34.38 consensus target. The quantum computing company shows concerning fundamentals with a P/S ratio of 421.36 and negative profitability metrics, including a -2,001.59% net income margin. Recent quarterly earnings have been mixed, missing expectations in Q4 2025 and Q2 2026 while beating in Q1 2026.

While analyst optimism remains high with 100% buy ratings, significant financial risks persist including ongoing losses, negative cash flow projections for 2026, and multiple fraud investigations. The stock faces substantial execution risk in the competitive quantum computing space, though long-term potential exists if the company can achieve commercial scalability and positive cash flow generation.